In an adult with an acute non‑variceal upper or lower gastrointestinal bleed, can tranexamic acid be used to stop the bleed, and what are the recommended dose, duration, and contraindications?

Tranexamic Acid for Acute GI Bleeding

Tranexamic acid should NOT be routinely used for acute non-variceal upper or lower gastrointestinal bleeding, as the highest quality evidence shows no mortality benefit and an increased risk of venous thromboembolism, particularly in patients with liver disease. 1

Key Evidence Against Routine Use

The most definitive evidence comes from a large randomized placebo-controlled trial of 12,009 patients with acute upper GI bleeding (nearly 50% with suspected variceal bleeding). 1 This trial found:

• No reduction in death due to bleeding within 5 days (primary outcome) 1
• Nearly 2-fold increase in venous thromboembolic events in the tranexamic acid group compared to placebo 1
• The thrombotic risk was concentrated in patients with liver disease/suspected variceal bleeding 1

Specific Contraindications

Variceal Bleeding

Tranexamic acid should absolutely not be used in patients with cirrhosis and active variceal bleeding. 1 The 2022 EASL guidelines provide a strong recommendation against its use in this population due to:

• No beneficial effect on bleeding outcomes 1
• Increased risk of venous thromboembolism 1
• The hypofibrinolytic state already present in critically ill cirrhotic patients 1

Historical Context vs. Current Practice

While older meta-analyses suggested potential mortality benefits from tranexamic acid in upper GI bleeding 1, 2, 3, these studies have critical limitations:

• Conducted before modern endoscopic therapy and high-dose PPI use 1
• Small sample sizes with methodological weaknesses 3
• When limited to trials at low risk of bias, mortality benefits disappeared 1

The 2002 British Society of Gastroenterology guidelines noted that while tranexamic acid appeared to reduce surgical intervention, it did not reduce rebleeding, and the evidence was skewed by questionable trial quality. 1

Current Standard of Care Instead

For non-variceal upper GI bleeding, the evidence-based approach is:

• High-dose IV PPI therapy: 80 mg bolus followed by 8 mg/hour infusion for 72 hours after successful endoscopic hemostasis 1
• Early endoscopy within 24 hours with appropriate endoscopic hemostasis for high-risk lesions 1
• Clips or thermocoagulation (alone or with epinephrine injection) for active bleeding or visible vessels 1

Exception: Trauma Setting Only

The only clinical scenario where tranexamic acid has strong evidence is in trauma-related bleeding (not GI bleeding):

• 1 g IV over 10 minutes, followed by 1 g over 8 hours 1
• Must be given within 3 hours of injury 1
• This is based on the CRASH-2 trial in trauma patients, which is not applicable to spontaneous GI bleeding 1

Clinical Pitfall to Avoid

Do not extrapolate trauma bleeding data to GI bleeding. The pathophysiology differs significantly—GI bleeding often involves portal hypertension, mucosal lesions requiring endoscopic therapy, and different coagulation profiles, particularly in cirrhotic patients who may already be hypofibrinolytic. 1

Ongoing Research

The HALT-IT trial (12,000 patients with acute upper or lower GI bleeding) may provide additional clarity, but until those results are available and change practice, tranexamic acid should be confined to clinical trials for GI bleeding. 1, 4